Organon & Co (OGN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $3.65B
Last updated: Nov 17, 2026 at 11:06 AM ET
Organon & Co (OGN) P/E Ratio & Valuation History
Organon (OGN) trades at 4.6x trailing earnings and 0.6x sales. Its P/E of 4.6x is above its 5-year median of 4.3x. Its forward P/E is 5.1x. The median P/E across 8 similar companies is 27.3x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 9.8% lower over the next year. Its free cash flow yield is 18.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 4.6x |
| Forward P/E | 5.1x |
| Price to sales | 0.6x |
| Price to book | 3.1x |
| EV/EBITDA | 8.4x |
| Price to FCF | 5.4x |
| EV/FCF | 15.9x |
| PEG | N/A |
| FCF yield | 18.5% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 4.6x | 4.3x | N/A |
| P/S | 0.6x | 0.7x | N/A |
Valuation History
Over the 5 year ends shown, its P/E ranged from 2.0x in 2025 to 5.6x in 2022. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $7.17 | 2.0x | 0.3x | 2.5x |
| 2024 | $14.92 | 3.6x | 0.6x | 8.2x |
| 2023 | $14.42 | 3.5x | 0.6x | N/A |
| 2022 | $27.93 | 5.6x | 1.2x | N/A |
| 2021 | $30.45 | 4.8x | 1.2x | N/A |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About OGN
What is OGN's forward P/E ratio?
Organon has a forward P/E ratio of 5.1x.
Is OGN stock overvalued?
GNG's valuation label for OGN is Undervalued. Its P/E of 4.6x compares with a median of 27.3x across 8 similar companies.
What is OGN's price to sales ratio?
Organon has a price to sales ratio of 0.6x.
What is Organon's average P/E ratio over 5 years?
Organon's median P/E over the last 5 years is 4.3x, from 59 month-end values through Oct 2026.
OGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors